Elanco Animal Health (NYSE:ELAN) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen upgraded shares of Elanco Animal Health (NYSE:ELAN) from a buy rating to a strong-buy rating in a research report sent to investors on Monday morning.

Other analysts have also issued research reports about the company. Barclays began coverage on Elanco Animal Health in a report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 target price for the company. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Stifel Nicolaus increased their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. UBS Group raised their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Zacks Research lowered shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.78.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $24.54 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $24.84. The business has a 50 day simple moving average of $22.55 and a two-hundred day simple moving average of $19.78. The stock has a market capitalization of $12.19 billion, a PE ratio of 409.07, a P/E/G ratio of 3.41 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the business earned $0.13 EPS. The company’s quarterly revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, research analysts predict that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Activity at Elanco Animal Health

In related news, insider Rajeev A. Modi purchased 4,500 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were acquired at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the purchase, the insider owned 123,082 shares of the company’s stock, valued at $2,625,339.06. This trade represents a 3.79% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was bought at an average cost of $21.30 per share, with a total value of $213,000.00. Following the acquisition, the director owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. The trade was a 8.21% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 43,450 shares of company stock worth $937,883 in the last quarter. 0.89% of the stock is currently owned by company insiders.

Institutional Trading of Elanco Animal Health

Several large investors have recently added to or reduced their stakes in ELAN. SJS Investment Consulting Inc. lifted its holdings in shares of Elanco Animal Health by 2,563.5% during the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after purchasing an additional 1,333 shares during the period. Huntington National Bank raised its position in Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after buying an additional 1,087 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its stake in Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after acquiring an additional 951 shares during the last quarter. Finally, Fifth Third Bancorp increased its stake in shares of Elanco Animal Health by 3,018.3% in the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock worth $58,000 after acquiring an additional 2,807 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.